GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing

Project Information

GATBIO NEXT

Grant agreement ID: 101114204

DOI

10.3030/101114204

Project closed

EC signature date 31 May 2023

Start date 1 June 2023

End date 31 May 2024

Funded under

• European innovation ecosystems

Total cost

No data

EU contribution

€ 75 000,00

Coordinated by

GAT BIOSCIENCES SL
Spain

Periodic Reporting for period 1 - GATBIO NEXT (GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing)

Reporting period: 2023-06-01 to 2024-05-31

Summary of the context and overall objectives of the project

GAT Biosciences S.L. (GATBIO) is a preclinical stage Biotech SME developing next generation of accessible and non-injected (oral) biopharmaceuticals through proprietary and sustainable microalgal biofactories. Our first candidate is GB-AF-004, an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases (IBDs). GB-AF-004 has the potential to highly impact the quality of life of millions of IBD’s patients worldwide as an affordable, low toxicity and long-term efficacy therapy for Ulcerative Colitis and Crohn's patients.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

GATBIO’s WomenTechEu Project has explored the best therapeutic positioning for GB-AF-004, based on a deep analysis of current therapeutic options for IBD and their limitations, working in collaboration with leaders of opinion in the clinical management of IBD.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Biologic anti-inflammatory therapies have already proven to be highly effective treatments for the induction and remission control of IBD's flares. Still, all available anti-inflammatory biologics are administered by injection and their systemic administration is related to site-effects and middle-terms loss of efficacy. GB-AF-004, a new class of anti-inflammatory antibody of enhanced properties to harsh intestinal atmosphere, has the potential to become the first oral anti-inflammatory biologic for IBDs management, acting specifically and locally in the damaged intestinal tissue without systemic immunosuppression and for long-term non-invasive, accessible and affordable treatments. IBDs includes a range of chronic and painful autoimmune diseases affecting locally the intestine, affecting patients from their youth and throughout life and of unknown causes. More than 10 million people are affected by IBD.